Efficacy of Metronidazole Gel Combined with Probiotics in the Treatment of Bacterial Vaginitis and its Effect on Vaginal Microenvironment
Objective To investigate the clinical efficacy of metronidazole gel combined with probiotics in the treatment of bacterial vaginitis(BV)and its effect on vaginal microenvironment.Methods A total of 60 BV patients admitted to Guixi Maternal and Child Health Hospital from November 2019 to November 2022 were collected and divided into control group and observation group according to random number table method,with 30 patients in each group.The control group was treated with metronidazole gel,and the observation group was treated with probiotics on the basis of the control group.The clinical efficacy,symptom improvement(vulva pruritus,vaginal burning,fishy odor,abnormal leucorrhea),vaginal microenvironment(vaginal pH value,vaginal secretion Nugent score),vaginal cleanliness and recurrence were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(P＜0.05).The symptoms relief time(vulva pruritus,vaginal burning,fishy odor,abnormal leucorrhea)in the observation group were shorter than those in the control group(P＜0.05).After treatment,the vaginal pH value and Nugent score of the two groups were lower than those before treatment,and the vaginal pH value and Nugent score of the observation group were lower than those of the control group(P＜0.05).The normal rate of vaginal cleanliness in the two groups after treatment was higher than that before treatment,and the normal rate of vaginal cleanliness in the observation group was higher than that in the control group(P＜0.05).At 3 months after treatment,the recurrence rate of the observation group was lower than that of the control group(P＜0.05).Conclusion Metronidazole gel combined with probiotics is effective in the treatment of bacterial vaginitis,which can accelerate symptom relief,improve vaginal microenvironment and cleanliness,and reduce the recurrence rate of patients.
万方数据
维普
